A detailed history of Fjarde Ap Fonden transactions in Biogen Inc. stock. As of the latest transaction made, Fjarde Ap Fonden holds 31,721 shares of BIIB stock, worth $4.65 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
31,721
Previous 27,821 14.02%
Holding current value
$4.65 Million
Previous $6 Million 2.5%
% of portfolio
0.06%
Previous 0.07%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$189.07 - $236.8 $737,373 - $923,520
3,900 Added 14.02%
31,721 $6.15 Million
Q1 2024

Apr 25, 2024

BUY
$212.02 - $267.71 $360,434 - $455,106
1,700 Added 6.51%
27,821 $6 Million
Q4 2023

Feb 14, 2024

BUY
$222.59 - $267.94 $22,259 - $26,794
100 Added 0.38%
26,121 $6.76 Million
Q3 2023

Oct 23, 2023

SELL
$253.3 - $285.89 $151,980 - $171,534
-600 Reduced 2.25%
26,021 $6.69 Million
Q2 2023

Aug 02, 2023

SELL
$275.25 - $318.06 $192,675 - $222,642
-700 Reduced 2.56%
26,621 $7.58 Million
Q1 2023

May 15, 2023

SELL
$256.56 - $292.34 $51,312 - $58,467
-200 Reduced 0.73%
27,321 $7.6 Million
Q4 2022

Feb 14, 2023

SELL
$252.44 - $306.72 $1.19 Million - $1.44 Million
-4,700 Reduced 14.59%
27,521 $7.62 Million
Q2 2022

Aug 11, 2022

SELL
$187.54 - $223.02 $1.2 Million - $1.43 Million
-6,400 Reduced 16.57%
32,221 $6.57 Million
Q1 2022

May 13, 2022

SELL
$193.77 - $244.14 $794,457 - $1 Million
-4,100 Reduced 9.6%
38,621 $8.13 Million
Q4 2021

Feb 15, 2022

SELL
$223.92 - $287.77 $335,880 - $431,655
-1,500 Reduced 3.39%
42,721 $10.3 Million
Q3 2021

Nov 15, 2021

SELL
$282.99 - $369.05 $198,093 - $258,335
-700 Reduced 1.56%
44,221 $12.5 Million
Q2 2021

Aug 12, 2021

SELL
$259.0 - $414.71 $802,900 - $1.29 Million
-3,100 Reduced 6.46%
44,921 $15.6 Million
Q1 2021

May 17, 2021

SELL
$242.95 - $284.63 $170,065 - $199,241
-700 Reduced 1.44%
48,021 $13.4 Million
Q4 2020

Feb 12, 2021

SELL
$236.26 - $355.63 $637,902 - $960,201
-2,700 Reduced 5.25%
48,721 $11.9 Million
Q3 2020

Nov 13, 2020

SELL
$264.77 - $305.71 $211,816 - $244,567
-800 Reduced 1.53%
51,421 $14.6 Million
Q2 2020

Aug 13, 2020

BUY
$258.66 - $342.55 $181,062 - $239,785
700 Added 1.36%
52,221 $14 Million
Q1 2020

May 11, 2020

SELL
$268.85 - $341.04 $457,045 - $579,768
-1,700 Reduced 3.19%
51,521 $16.3 Million
Q3 2019

Oct 31, 2019

SELL
$217.44 - $243.88 $543,600 - $609,700
-2,500 Reduced 4.49%
53,221 $12.4 Million
Q2 2019

Jul 17, 2019

SELL
$219.29 - $241.72 $833,302 - $918,536
-3,800 Reduced 6.38%
55,721 $13 Million
Q1 2019

Apr 29, 2019

BUY
$216.71 - $338.96 $2.6 Million - $4.06 Million
11,982 Added 25.2%
59,521 $14.1 Million
Q4 2018

Jan 31, 2019

SELL
$278.5 - $352.75 $2.31 Million - $2.93 Million
-8,300 Reduced 14.86%
47,539 $14.3 Million
Q3 2018

Nov 09, 2018

SELL
$293.51 - $383.83 $928,665 - $1.21 Million
-3,164 Reduced 5.36%
55,839 $19.7 Million
Q2 2018

Jul 12, 2018

BUY
$257.52 - $306.91 $75,968 - $90,538
295 Added 0.5%
59,003 $17.1 Million
Q1 2018

May 07, 2018

BUY
$260.13 - $367.91 $30,695 - $43,413
118 Added 0.2%
58,708 $16.1 Million
Q4 2017

Feb 12, 2018

BUY
$307.64 - $344.58 $2.61 Million - $2.92 Million
8,480 Added 16.92%
58,590 $18.7 Million
Q3 2017

Nov 07, 2017

BUY
$281.15 - $329.69 $23,897 - $28,023
85 Added 0.17%
50,110 $15.7 Million
Q2 2017

Aug 08, 2017

BUY
N/A
50,025
50,025 $13.6 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Fjarde Ap Fonden Portfolio

Follow Fjarde Ap Fonden and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

News

Stay updated on Fjarde Ap Fonden with notifications on news.